<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788099</url>
  </required_header>
  <id_info>
    <org_study_id>APL-A-010-08</org_study_id>
    <nct_id>NCT00788099</nct_id>
  </id_info>
  <brief_title>Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas</brief_title>
  <official_title>Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaMar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in
      Combination with Sorafenib or Gemcitabine in Patients with Advanced Solid Tumors or Lymphomas
      to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of plitidepsin in
      combination with sorafenib or gemcitabine in patients with advanced solid tumors or
      lymphomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in
      Combination with Sorafenib or Gemcitabine in Patients with Advanced Solid Tumors or Lymphomas
      to determine the maximum tolerated dose (MTD) and the recommended dose (RD), the
      pharmacokinetics (PK) of these combinations, drug-drug PK interactions, preliminary
      information on the clinical antitumor activity of these combinations in solid tumors,perform
      a preliminary pharmacogenomic (PGx) study of potential biomarkers of sensitivity/resistance
      to these drugs combinations and of prognostic markers of the treatment outcome in tumor
      tissue sample.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) and the recommended dose (RD) of plitidepsin in combination with sorafenib or gemcitabine in patients with advanced solid tumors or lymphomas.</measure>
    <time_frame>Along the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize safety profile and feasibility, pharmacokinetics, drug-drug interactions. To obtain information on antitumor activity.</measure>
    <time_frame>Along the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Lymphomas</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plitidepsin and Sorafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine and Plitidepsin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plitidepsin and Sorafenib</intervention_name>
    <description>Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine and Plitidepsin</intervention_name>
    <description>Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  ECOG performance status (PS) of ≤ 1

          -  Life expectancy ≥ 3 months

          -  Patients with histologically/cytologically confirmed diagnosis of advanced solid
             tumors or lymphomas (excluding B-cell derived lineage and/or primary cutaneous and/or
             leukemic disease) refractory to standard therapy and with reasonable chance to benefit
             from any of these combinations according to the investigator's opinion.

          -  Patients entered at the expansion cohort of the RD must have: a) measurable disease
             according to RECIST, or to International Working Group Criteria (IWC) for lymphoma
             patients or b) Evaluable disease by serum markers in the case of prostate and ovarian
             cancer (according to Prostate-Specific Antigen Working Group Recommendations (PSAWGR)
             and Gynecologic Cancer Intergroup (GCIG) specific criteria, respectively

          -  At least 4 weeks since last chemotherapy (6 weeks since nitrosoureas and mitomycin C),
             immunotherapy or any other pharmacological treatment and radiotherapy. In the case of
             hormone-sensitive cancer progressing while on hormone therapy (i.e., breast, prostate
             cancer), hormone therapy must be either stopped 4 weeks before or continued during the
             trial

          -  Adequate bone marrow, renal, hepatic, and metabolic function (assessed ≤ 7 days before
             inclusion in the study): a) Platelet count ≥100 x109/L (≥ 75 x 109/L for lymphoma
             patients), hemoglobin ≥9.0 g/dL (≥ 8.0 g/dL for lymphoma patients) and absolute
             neutrophil count (ANC) ≥1.5 x109/L (≥1.0 x109/L for lymphoma patients). b) Aspartate
             Aminotransferase (AST) and Alanine Aminotransferase (ALT): ≤ 3.0 x the upper limit of
             normal (ULN), independently of the presence of liver metastases. c) AP ≤2.5 x ULN (≤5
             x ULN in case of extensive bone metastases). d) Total bilirubin ≤1.5 x ULN (unless due
             to indirect hyperbilirubinemia for the gemcitabine combination arm only). e)
             Calculated CrCl: ≥ 40 mL/minute (by means of Crockroft and Gault´s formula). f) CPK ≤
             2.5 x ULN. g) Albumin ≥2.5 g/dL. h) Troponin I ≤ULN

          -  Recovery to grade ≤1 from any AE derived from previous treatment (excluding alopecia
             of any grade and peripheral neuropathy ≤ grade 2)

          -  LVEF by ECHO or MUGA above the lower normal limit.

          -  Women of childbearing potential must have a negative serum pregnancy test before study
             entry. Both women and men must agree to use a medically acceptable method of
             contraception throughout the treatment period and for 3 months after discontinuation
             of treatment. Acceptable methods of contraception include complete abstinence,
             intrauterine device (IUD), oral contraceptive, subdermal implant and double barrier

          -  Voluntarily signed and dated written informed consent prior to any specific study
             procedure.

        Exclusion Criteria:

          -  Previous treatment with any of the study drugs (in the expansion cohort at the RD).

          -  Concomitant diseases/conditions:

               -  History or presence of unstable angina, myocardial infarction, valvular heart
                  disease or congestive heart failure.

               -  Previous mediastinal radiotherapy.

               -  Previous treatment with doxorubicin at cumulative doses in excess of 450 mg/m2

               -  Symptomatic arrhythmia or any arrhythmia requiring ongoing treatment, and/or
                  prolonged QT-QTc &gt; to grade 1.

               -  Active uncontrolled infection.

               -  Myopathy or any clinical situation that causes significant and persistent
                  elevation of CPK (&gt;2.5 x ULN in two different determinations performed with one
                  week apart).

               -  Limitation of the patient's ability to comply with the treatment or follow-up
                  protocol.

               -  Any other major illness that, in the Investigator's judgment, will substantially
                  increase the risk associated with the patient's participation in this study.

               -  Peripheral neuropathy &gt;grade 2

          -  Symptomatic, progressive or requiring-corticosteroids documented brain metastases or
             leptomeningeal disease. Controlled and stable brain metastases without steroids are
             allowed

          -  Men or women of childbearing potential who are not using an effective method of
             contraception as previously described; women who are pregnant or breast feeding

          -  Patients who have had radiation therapy in greater than 35% of the bone marrow

          -  History of previous bone marrow and/or stem cell transplantation. (Not for patients
             treated at RD in the expansion cohort)

          -  High transfusional requirements (&gt; 2 packages of red blood cells and/or 1 platelets
             transfusion) in the 30 days prior to inclusion in the study

          -  Participation in another clinical trial or concomitant treatment with any
             investigational product in the 30-day period prior to inclusion in the study.

          -  For sorafenib treatment only: a) Hypersensitivity to sorafenib or any component of the
             formulation. b) Need of chronic exposure to antacids, H-2 antagonists or proton-pump
             inhibitors. c) Current need for anticoagulation treatment (including low dose warfarin
             and LMWH treatment at full anticoagulant doses).

          -  Abnormal thyroid function [as per normal serum thyroid stimulating hormone (TSH)
             within 14 days of first dose of study treatment).

          -  Uncontrolled arterial hypertension (≥160/100) despite optimal medical therapy.

          -  Child-Pugh grade C hepatic cirrhosis of any cause

          -  For gemcitabine treatment only:

               -  Hypersensitivity to gemcitabine or any component of the formulation.

               -  Impending need for palliative radiotherapy to ameliorate painful metastases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark N. Stein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Charles Soria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cancer Institute of New Jersey (CINJ)</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2008</study_first_submitted>
  <study_first_submitted_qc>November 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2008</study_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Pharmamar USA</name_title>
    <organization>Pharmamar USA</organization>
  </responsible_party>
  <keyword>Aplidin</keyword>
  <keyword>Plitidepsin</keyword>
  <keyword>Tumors</keyword>
  <keyword>Lymphomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

